Stockscreener 앱 받기
102.61
0.37%
0.38
시간 외 거래:
102.61
Abbott Laboratories 주식(ABT)의 최신 뉴스
Two Medical Device Dividend Giants, One Better Buy: Medtronic vs. Abbott - AOL.com
Abbott Laboratories Stock (ABT) Opinions on Analyst Buy Rating Reiteration - Quiver Quantitative
Is Abbott Laboratories (ABT) Reasonably Priced After Its FDA Win? - simplywall.st
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
Abbott Laboratories stock gains as Citi lifts price target and guidance stays firm - ad-hoc-news.de
Abbott Cancer Diagnostics Targets Prospective Studies for MCED Test a Year After Launch - GenomeWeb
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio - Yahoo Finance
Abbott Laboratories Share Price Today (ABT) | Live Chart, News & Stock Market - TechGraph
Abbott Laboratories stock heads into the open after a 0.4% dip - ad-hoc-news.de
Abbott Laboratories stock underperforms Thursday when compared to competitors - MarketWatch
Top Research Reports for Goldman Sachs, RTX & Abbott - finance.yahoo.com
Abbott Spinal Cord Stimulator Explant Surgery Required After Device Failure: Lawsuit - AboutLawsuits.com
Abbott Laboratories stock falls after FDA approval - ad-hoc-news.de
Abbott Laboratories stock before the bell falls 2.6 percent - ad-hoc-news.de
Abbott Laboratories (ABT) Secured FDA Approval, Is It Still 11% Below Fair Value? - simplywall.st
Abbott Wins FDA Clearance for Dual-Energy AFib Catheter - finance.biggo.com
Abbott partners with Sengkang General Hospital to advance early detection of muscle loss in Singapore - BioSpectrum Asia
Abbott Is Selling Sterility as a Feature. In Liquid Formula It Is Already the Rule. - marlerblog.com
Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain? - Yahoo Finance
Abbott garners FDA nod for its TactiFlex catheter to treat AFib - Fierce Biotech
Abbott’s dual ablation catheter lands FDA approval - Yahoo Finance
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $112 - Moomoo
Abbott Laboratories stock gains after FDA approval and strong guidance - ad-hoc-news.de
Abbott Laboratories stock heads into the open after a modest loss - ad-hoc-news.de
Here's Why Abbott (ABT) Fell More Than Broader Market - finance.yahoo.com
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond - The Motley Fool
FDA approves new Abbott catheter capable of PFA and radiofrequency ablation - Cardiovascular Business
Abbott wins FDA approval for dual-energy ablation catheter - MedTech Dive
Abbott receives FDA approval for AFib ablation catheter - grafa.com
Abbott Laboratories (ABT) Won FDA Approval For Its TactiFlex Duo Catheter - simplywall.st
Abbott scores another win at UPC with SiBio preliminary injunction - IAM Patent
Abbott receives FDA approval for dual-energy heart ablation catheter By Investing.com - Investing.com Canada
Abbott wins FDA nod for cardiac ablation catheter (ABT:NYSE) - Seeking Alpha
The FDA Clears an Abbott Product - marketscreener.com
10.5 million people in the U.S. live with hearts that beat too fast, too slow or irregularly. Abbott gets FDA approval. - Stock Titan
Abbott Laboratories stock holds firm after July earnings - AD HOC NEWS
Abbott Laboratories (NYSE:ABT): Can Heart Research Lift Its Next Move? - Kalkine Media
Abbott Blocks Rival's Glucose Monitor Sales In Europe - Law360
Abbott Laboratories stock holds valuation premium amid steady earnings - ad-hoc-news.de
Abbott Laboratories (ABT) Stock Analysis: Analyst Consensus Reveals a 10.96% Upside Potential - DirectorsTalk Interviews
Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets - simplywall.st
Abbott Laboratories stock holds near $108 after strong Q2 - AD HOC NEWS
Abbott Laboratories Profile: Recipients - opensecrets.org
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript - Fortune
How New Diabetes, Cardiac, Nutrition and Cancer Tools At Abbott Laboratories (ABT) Have Changed Its Investment Story - simplywall.st
Abbott CFO Philip P. Boudreau Retains 70,784 Shares After Forfeiting 388 Shares at $110.36 Each - Kalkine Media
Ferguson Wellman Capital Management Inc. Sells 136,385 Shares of Abbott Laboratories $ABT - InsuranceNewsNet
Renal Denervation Market Size, Share & Trends Analysis - GlobeNewswire Inc.
US companies face rise in cyber attacks - Reuters
Abbott Laboratories CFO Philip P. Boudreau Reports Sale of 388 Shares at $110.36 in SEC Form 4 Filing - Kalkine Media
Abbott Laboratories VP John A. McCoy Jr. Reports Share Sales on September 1-2, 2026 - Kalkine Media
Abbott Laboratories (ABT) CFO reports small tax-related share disposal - Stock Titan
Abbott Laboratories stock gains support from fresh earnings and guidance - AD HOC NEWS
Abbott ablation device effective at 1 year in complex cases - MedTech Dive
Small Abbott (NYSE: ABT) insider sale from vested stock award - Stock Titan
Abbott Laboratories stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
0.69%
0.01%
자본화:
|
볼륨(24시간):